Business Context and Reporting Period
Company: Ekso Bionics Holdings, Inc. (Ticker: EKSO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: The Company designs and markets wearable powered and non-powered exoskeletons for neurorehabilitation (EksoHealth segment) and industrial applications (EksoWorks segment). Key products include the EksoNR, Ekso Indego Therapy, Ekso Indego Personal, and the EVO industrial exoskeleton.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $4,129 | $4,607 | $12,835 | $13,432 |
| Gross Profit | $2,209 | $2,456 | $6,797 | $6,710 |
| Gross Margin | 53.5% | 53.3% | 53.0% | 50.0% |
| Net Loss | $(2,072) | $(3,365) | $(7,917) | $(11,984) |
| Diluted EPS | $(0.10) | $(0.24) | $(0.42) | $(0.88) |
| Cash and Restricted Cash | $8,292 | $9,937 | $8,292 | $9,937 |
| Unrestricted Cash | $6,292 | N/A | $6,292 | N/A |
| Total Debt (Notes Payable) | $5,356 | N/A | $5,356 | N/A |
Note: Total Debt includes $2,000 in BoC Term Loan and $3,356 in Parker Hannifin Promissory Note (net of discounts). Unrestricted cash is calculated after deducting $2,000 restricted cash required by loan covenants.
Material Changes vs. Prior Period
- Revenue Decline: Q3 2024 revenue decreased 10% year-over-year to $4.1 million, driven by lower Enterprise Health device shipments and reduced EksoWorks volume. Nine-month revenue decreased 4% to $12.8 million.
- Improved Margins: Gross margin improved to 53.5% in Q3 2024 (from 53.3% in Q3 2023) and 53.0% for the nine months (from 50.0% in 2023), attributed to supply chain cost savings and reduced service costs.
- Reduced Operating Expenses: Total operating expenses decreased 10% in Q3 and 18% for the nine months compared to the prior year periods, primarily due to lower headcount, reduced consultant usage, and lower discretionary payroll.
- Net Loss Reduction: Net loss narrowed significantly to $2.1 million in Q3 2024 from $3.4 million in Q3 2023. This improvement was aided by a $0.6 million unrealized gain on foreign exchange and a $0.4 million gain on warrant revaluation.
- Financing Activity: The Company raised approximately $9.0 million in net proceeds during the nine months ended September 30, 2024, via a January 2024 registered direct offering ($3.9 million) and a September 2024 underwritten public offering ($5.0 million).
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for 12 months from the issuance date. The Company has an accumulated deficit of $247.1 million and expects to continue generating operating losses. Additional funding is required to support operations.
- Reimbursement Catalyst: In April 2024, CMS approved a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal device. Management expects this to drive demand in the Personal Health business line.
- Regulatory Risks: The Company is in the process of obtaining CE Certificates of Conformity under the EU MDR for its acquired products. Failure to comply by the December 31, 2028 deadline would prevent sales in the EU.
- Debt Covenants: The Company must maintain cash on hand equivalent to the outstanding principal balance of its BoC Term Loan ($2.0 million), which restricts liquidity.
- Customer Concentration: In Q3 2024, one customer accounted for 26% of total revenue. Two customers held 14% and 13% of total accounts receivable as of September 30, 2024.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any planned future financings given the "substantial doubt" going concern disclosure and $6.3 million in unrestricted cash.
- Reimbursement Execution: Monitor actual sales volume growth of the Ekso Indego Personal device following the April 2024 CMS reimbursement approval.
- Debt Servicing: Review the schedule for the Parker Hannifin Promissory Note ($1,250 due in 2025) and ensure cash flow projections support these payments.
- EU Regulatory Status: Track progress on CE Mark certification for the Ekso Indego Therapy and Personal devices to ensure access to the EMEA market.
- Customer Concentration: Assess the risk associated with the single customer representing 26% of Q3 revenue and the potential impact of their order cycles.